Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avelumab - Merck KGaA

Drug Profile

Avelumab - Merck KGaA

Alternative Names: Anti-CD274-monoclonal-antibody; Anti-PD-L1 monoclonal antibody - EMD Serono; Anti-PD-L1 monoclonal antibody - Merck KGaA; BAVENCIO; MSB-0010718C; PF-06834635

Latest Information Update: 26 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono; Merck KGaA
  • Developer AIO Studien gGmbH; Array BioPharma; Chong Kun Dang; Dana-Farber Cancer Institute; Debiopharm; eFFECTOR Therapeutics; EMD Serono; Forty Seven; Fred Hutchinson Cancer Research Center; Gachon University Gil Medical Center; Hellenic Cooperative Oncology Group; Hoosier Cancer Research Network; Hospices Civils de Lyon; Johannes Gutenberg-University Mainz; M. D. Anderson Cancer Center; Merck KGaA; National Cancer Institute (USA); National Cancer Institute Slovakia; Netherlands Cancer Institute; Pfizer; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Transgene; University College London; University of Birmingham; University of California, San Diego; University of Iowa; University of North Carolina at Chapel Hill; Vaccinex; Vanderbilt-Ingram Cancer Center; VAXIMM; Verastem Oncology; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Merkel cell carcinoma; Renal cell carcinoma; Urogenital cancer
  • Phase III Breast cancer; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Phase II Bladder cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Gestational trophoblastic disease; Glioblastoma; Haemangiosarcoma; Hodgkin's disease; Intestinal cancer; Leiomyosarcoma; Nasopharyngeal cancer; Neuroendocrine tumours; Oesophageal cancer; Osteosarcoma; Penile cancer; Peripheral T-cell lymphoma; Peritoneal cancer; Prostate cancer; Recurrent respiratory papillomatosis; Small cell lung cancer; Squamous cell cancer; Thymoma
  • Phase I/II Liposarcoma; Lymphoma; Oropharyngeal cancer; Pancreatic cancer
  • Phase I Acute myeloid leukaemia; Follicular lymphoma; Liver cancer; Meningioma

Most Recent Events

  • 11 Nov 2019 Efficacy and adverse events data from a phaseIII JAVELIN Gastric 100 trial release by EMD Serono and Pfizer
  • 09 Nov 2019 Updated interim efficacy and safety data from the phase Ib/II CLASSICAL-Lung trial in Non-small cell lung cancer released by Vaccinex
  • 06 Nov 2019 EMD Serono and Merck complete a phase II trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer in the UK, USA and Belgium (IV) (NCT03704467)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top